The Day In Review: Pfizer Inc. Invests In Monogram Biosciences

Published: May 08, 2006

May 8, 2006 -- Pfizer made a $25 million investment in Monogram Biosciences, with the goal of bringing Monogram’s HIV test to a worldwide market; Kos paid $165 million for an exclusive license to Flutiform, a fixed-dose inhaler for asthma; according to InterMune, a preclinical study illuminated the mechanism of its pulmonary fibrosis compound; Teva released data from a 10-year study of MS drug Copaxone; Cytogen paid $6 million to Berlex to buy out the royalties on Quadramet; Vernalis and Endo Pharma released positive Phase III data from a Frova trial against menstrual migraine; deCODE Genetics has identified a genetic variation that increases the chance of prostate cancer by 60%; CancerVax has officially become Micromet; and Panacos moved 14% higher after an analyst suggested that Gilead might buy the company at a 100% premium. The Centient Biotech 200™ rose 4 points to 3800.57, an increase of .10%. More details...

Back to news